Want to see AU:CYV full AI Analyst Report?
CYV Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.62
Previous CloseN/A
Volume1.19M
Average Volume (3M)0.00
Market Cap
AU$16.42M
Enterprise ValueAU$499.74
Total Cash (Recent Filing)AU$22.13M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)<0.1
Beta2.09
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,367,978,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-3.65
Price to Sales (P/S)29392.74
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$790.29K
Bulls Say, Bears Say
Bulls Say
Targeted Biologic TherapyOpthea's lead asset targets VEGF‑C/D and is being developed as a complement to anti‑VEGF‑A therapies. That mechanism creates a durable strategic niche in retinal disease, supporting combination regimens, differentiation versus mono‑VEGF approaches and potential partner interest if clinical results validate the approach.
Positive Gross Profit HistoryReporting positive gross profit despite a pre‑commercial profile indicates the company has managed direct production and trial costs efficiently to date. If scaled, this suggests potential for sustainable product margins relative to peers, improving the structural economics upon commercialization.
Debt Eliminated In FY2025Eliminating debt materially reduces near‑term financial obligations and interest exposure, lowering default risk and improving flexibility for R&D investment or partnership structuring. This strengthens short‑to‑medium term solvency even while external funding may still be required for operations.
Bears Say
High And Persistent Cash BurnSustained operating and free cash outflows of roughly -159M per year create continuous dependence on external financing. Over the coming months this structural cash burn raises dilution risk, constrains strategic optionality and makes long‑term R&D plans contingent on successful capital raises or partnerships.
Negative Equity And Shrinking AssetsMaterial negative equity and a sharply reduced asset base reflect accumulated losses and weakened capital reserves. This impairs the company's ability to absorb clinical setbacks, reduces borrowing capacity, and can deter counterparties, making structural recovery and scaling more challenging without fresh capital.
Very Small, Volatile RevenueRevenue volatility and near‑zero commercial receipts indicate the business remains pre‑commercial and revenue depends on trial success and approvals. This structural revenue uncertainty undermines self‑funding prospects and means long‑term viability hinges on successful development, regulatory outcomes, or partnering deals.
Opthea News
CYV FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.01 and its highest was AU$0.61 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is AU$16.42M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2026 which is in 22 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Mar 01, 2026. The company reported AU$0.258 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is 0.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,367,978,100 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of AU$0.258 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in AU:CYV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opthea Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-83.74%
Trailing 12-Months
Company Description
Opthea Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Recce Pharmaceuticals Ltd.
―